The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis
Authors
Keywords
-
Journal
CELLULAR ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-08
DOI
10.1007/s13402-020-00514-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The exosomal integrin α5β1/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration
- (2020) Xiaoduan Li et al. CELLULAR ONCOLOGY
- Targeting PI3K Signaling in Acute Lymphoblastic Leukemia
- (2019) Vanessa Sanchez et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
- (2019) Tian Tian et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts
- (2019) Mark A. Eckert et al. NATURE
- Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer
- (2019) Yangjiong Xiao et al. Frontiers in Oncology
- Recent advances in the clinical development of immune checkpoint blockade therapy
- (2019) Atefeh Ghahremanloo et al. CELLULAR ONCOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance
- (2018) Maria Luisa Gasparri et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts
- (2017) Irene Brana et al. Oncotarget
- Epidemiology of ovarian cancer: a review
- (2017) Reid Brett M. et al. Cancer Biology & Medicine
- A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
- (2016) J. E. Grilley-Olson et al. INVESTIGATIONAL NEW DRUGS
- A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors
- (2016) Christos E. Kyriakopoulos et al. INVESTIGATIONAL NEW DRUGS
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
- (2015) Seiji Mabuchi et al. GYNECOLOGIC ONCOLOGY
- PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
- (2014) HaiXia Li et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Tumorgrafts asIn VivoSurrogates for Women with Ovarian Cancer
- (2014) S. John Weroha et al. CLINICAL CANCER RESEARCH
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- Dual Inhibition of Phosphatidylinositol 3′-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach for Mucinous Adenocarcinoma of the Ovary
- (2014) Akiko Kudoh et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts
- (2014) Monique D. Topp et al. Molecular Oncology
- Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423
- (2014) Tomoko Kashiyama et al. PLoS One
- Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
- (2014) Corine M. Beaufort et al. PLoS One
- The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
- (2013) Zachary Dobbin et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Development of PI3K inhibitors: lessons learned from early clinical trials
- (2013) Jordi Rodon et al. Nature Reviews Clinical Oncology
- Evaluating cell lines as tumour models by comparison of genomic profiles
- (2013) Silvia Domcke et al. Nature Communications
- Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases
- (2012) Teresa G. Granda et al. INVESTIGATIONAL NEW DRUGS
- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations
- (2012) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells
- (2011) Euphemia Leung et al. CANCER BIOLOGY & THERAPY
- The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations
- (2011) H. Tanaka et al. CLINICAL CANCER RESEARCH
- Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
- (2011) Kian Behbakht et al. GYNECOLOGIC ONCOLOGY
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- CD95 promotes tumour growth
- (2010) Lina Chen et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now